2020 Annual Meeting | C217 - MS Across the Lifespan

Date Thursday 04/30/20

Time 07:00 AM - 09:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Le Hua, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to identify the comorbidities that impact disease management in MS; recognize the role of the aging immune system on MS disease progression and risks of DMT; and become familiar with utility of DMT and when to consider stopping DMT in older patients.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic

Event Timeline
07:00 AM - 07:05 AM	Introduction	Introduction Le Hua, MD, FAAN
07:05 AM - 07:40 AM	Speaker	The Aging Immune System Jennifer Graves, MD, PhD
07:40 AM - 08:20 AM	Speaker	Comorbidities in Older Patients with MS Ruth-Ann Marrie, MD, PhD
08:20 AM - 08:55 AM	Speaker	The Role of Disease-modifying Therapies in Older MS Patients Le Hua, MD, FAAN
08:55 AM - 09:00 AM	Q&A	Questions and Answers

Faculty Disclosures
Ruth-Ann Marrie, MD, PhD	The institution of Dr. Marrie has received research support from CIHR. The institution of Dr. Marrie has received research support from MS Canada. The institution of Dr. Marrie has received research support from National MS Society. The institution of Dr. Marrie has received research support from Crohn's and Colitis Canada. The institution of Dr. Marrie has received research support from US Department of Defense. The institution of Dr. Marrie has received research support from The Arthritis Society. The institution of Dr. Marrie has received research support from CMSC.
Jennifer Graves, MD, PhD	Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Graves has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MSJ. The institution of Dr. Graves has received research support from Octave. The institution of Dr. Graves has received research support from Sanofi. The institution of Dr. Graves has received research support from EMD Serono.
Le Hua, MD, FAAN	Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Bioscience. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapuetics. The institution of Dr. Hua has received research support from Genentech.

��ɫ��

��ɫ��